For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies…
Monolith
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards…
NanoTemper’s Monolith wins top global design award: Red Dot Award
NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal…
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD)…
NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021
NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly…
Are you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality…
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the…
Can bioanalytical tools solve your neurodegenerative disease research challenges? 4 questions to ask yourself
Despite extensive efforts, neurodegenerative diseases (ND) continue to feel like a pharmaceutical frontier. We have…
Characterize the true nature of intrinsically disordered proteins without immobilizing them
If you study neurodegenerative diseases (ND), you already know they are one of the most…